Infographics 10 Jan 2018 Infographic: All You Need to Know About Checkpoint Inhibitors Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […] January 9, 2018 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial Minoryx Therapeutics has dosed the first patient in its Phase II/III trial for patients with adrenomyeloneuropathy, a condition that affects 1 in 17,000 newborns worldwide. Minoryx Therapeutics focuses on the development of new drugs for orphan diseases like adrenomyeloneuropathy. The first two patients in ADVANCE, a Phase II/III clinical trial of MIN-102, have started their treatment. The trial, […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This Skin Patch Could Slow the Rate of Antibiotic Resistance Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […] January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email